医学
肿瘤科
免疫疗法
内科学
癌症研究
微卫星不稳定性
癌症
生物标志物
彭布罗利珠单抗
生物
生物化学
微卫星
基因
等位基因
作者
Oliver Klein,Damien Kee,Ben Markman,Matteo S. Carlino,Craig Underhill,Jodie Palmer,D. Power,Jonathan Cebon,Andreas Behren
出处
期刊:Cancer Cell
[Cell Press]
日期:2021-05-01
卷期号:39 (5): 592-593
被引量:42
标识
DOI:10.1016/j.ccell.2021.04.005
摘要
Tumor mutational burden (TMB) was initially shown to be of predictive value in non-small-cell lung cancer patients treated with anti-programmed cell death protein 1(PD-1)/programmed death-ligand 1 (PD-L1) agents (Chan et al., 2019; Jardim et al., 2021). More recently, Keynote 158, a clinical trial of pembrolizumab (anti-PD-1) monotherapy demonstrated an increased response rate in patients with TMBhigh tumors (≥10 mutations per megabase (MB) genome) in a pan-tumor cohort (Marabelle et al., 2020).
科研通智能强力驱动
Strongly Powered by AbleSci AI